Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Primary objective:
To determine the 6-month progression free survival of patients with recurrent glioblastoma
multiforme (GBM) treated with Erlotinib plus Sirolimus.
Secondary objectives:
To further define the safety and tolerability of Erlotinib plus Sirolimus when administered
to patients with recurrent GBM; and to evaluate progression free survival, radiographic
response and overall survival of patients with recurrent GBM treated with Erlotinib plus
Sirolimus.